Oops, there appears to be a problem

We are currently experiencing technical difficulties The LocalToolbox Technical Staff has been notified! If you need immediate assistance, please call 415-456-9800.

Couldn't open mncablev5_portal - Unknown database 'mncablev5_portal' Sjoberg's Cable | Local: News & Information
sjobergs_masthead
Unknown database 'mncablev5_local' Unknown database 'mncablev5_local'

Custom Search
Unknown database 'mncablev5_local' We are currently experiencing technical difficulties

The page you have selected is currently unavailable. Please try your link again. If you continue to have problems, contact the localtoolbox technical staff. The LocalToolbox Technical Staff has been notified! If you need immediate assistance, please call 415-456-9800.

DB ERROR = No database selected We are currently experiencing technical difficulties

The page you have selected is currently unavailable. Please try your link again. If you continue to have problems, contact the localtoolbox technical staff. The LocalToolbox Technical Staff has been notified! If you need immediate assistance, please call 415-456-9800.

DB ERROR = No database selected Unknown database 'mncablev5_portal'
Unknown database 'mncablev5_local' Unknown database 'mncablev5_local'
Today's Health Headlines
Chinese authorities are probing a local unit of global catering giant Compass Group Plc over mouldy and expired food found at a private school served by the group and said it would inspect other schools around the city.

German drugmaker Merck KGaA might agree partnership deals to jointly develop two of its most promising experimental medicines with a rival as early as this year, but more likely in 2019, its drug research and development chief said on Sunday.

An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.

Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals.

An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.

France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

(Reuters Health) - While symptoms like chest or belly pain might reasonably drive you to the emergency room with worries about a heart attack or appendicitis, your insurance company might decide not to pay if it turns out your fears were unfounded, a new study suggests.

(Reuters Health) - Playing golf is associated with better strength and balance, a sharper mind, a lower risk of heart disease and a longer life, according to public health experts who say more people should take up the sport.

(Reuters Health) - Hispanics in the U.S. have lower rates of death from heart disease overall than non-Hispanic whites, except in communities where Hispanics make up most of the population, a recent study finds.

Unknown database 'mncablev5_local' Unknown database 'mncablev5_local'
Welcome Sjoberg's Guest
Portal users and mncable users can login below
Browse RSS Feeds
click here when finished
Save Page Layout
Video
Unknown database 'mncablev5_local' Unknown database 'mncablev5_local'
loading